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SUMMARY Opioid-induced respiratory depression (OIRD) is a potentially fatal 
complication of treatment with opioids. Little is known about patient- and case-related 
factors associated with OIRD. One-hundred-and-five available case reports on OIRD in 
134 patients (12 years and older) in the perioperative, obstetric or emergency care setting, 
published since 1980, were retrieved from the literature. The most frequently reported 
case-related factors were: morphine use, perioperative setting and obstetrics, neuraxial or 
intravenous administration. The most frequently reported patient-related factors involved 
were: female gender, sleep-disordered breathing, obesity, renal impairment, pulmonary 
disease and CYP450 enzyme polymorphisms. While the analysis has limitations, it confirms 
that OIRD in the acute setting involves complex and interrelated factors and is a significant 
cause of preventable morbidity and mortality.
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Practice points
 ●  Opioid-induced respiratory depression (OIRD) is a potentially fatal complication 
of opioid use both in clinical (perioperative and acute/chronic pain relief) and 
nonclinical settings (misuse/abuse).
 ●  Since 1980, 105 case reports on critical OIRD in the acute care setting were published 
in the literature as retrieved from PubMed.
 ●  The majority of patients had no underlying comorbidities that placed them at 
increased risk for OIRD. Only 30–40% of cases had a comorbidity possibly related 
to the OIRD including sleep-disordered breathing, renal impairment, obesity and 
pulmonary disease, neurological disorders and polymorphisms of the CYP450 
enzyme system.
 ●  Most frequently reported opioid related to respiratory depression was morphine, 
followed by sufentanil and fentanyl. Neuraxial administration was the most frequent 
route associated with OIRD followed by intravenous dosing.
 ●  In case reports since 2000, complications in women were disproportionately more 
common, consistent with their higher opioid sensitivity. Advanced age was not a 
factor related to OIRD.
 ●  This analysis of case reports indicates that OIRD is a significant cause of preventable 
morbidity and mortality and that OIRD is difficult to predict. Dose titration to effect 
alongside comprehensive and frequent respiratory and level of consciousness 
monitoring remains the most important safeguard against preventable harm to 
undetected OIRD.
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Opioid-induced respiratory depression (OIRD) 
is a potentially fatal complication of opioid use 
in both acute and chronic pain therapy, and 
nonclinical settings, such as opioid misuse and 
addiction [1]. Although fatalities from OIRD 
in the clinical setting are well described in case 
reports, there is no compendium of patient and 
nonpatient-related factors that are common to 
these serious adverse events. We have previ-
ously published an analysis of case reports of 
OIRD in pediatric patients (0–12 years of age) 
and patients treated with opioids for chronic 
pain [2,3]. In the current study, we apply our 
methodology from earlier publications to the 
cohort of case reports describing OIRD in ado-
lescent and adult patients with OIRD in acute 
care settings. Our prior analysis of OIRD case 
reports in pediatric patients revealed that fatal 
OIRD was associated with children receiving 
codeine following tonsillectomy or adenoid-
ectomy. Our publication coincided with a US 
FDA black box warning of codeine use in these 
procedures, prompted in part by ten deaths and 
three reported overdoses associated with codeine 
in the period 1969–2012 [4]. This association 
strengthened our suspicion that a careful analysis 
of case reports may reveal specific demographic, 
pharmacological or clinical covariates that con-
fer additional risk for OIRD. We describe our 
findings for patients receiving opioids for acute 
pain, including obstetrical pain, and patients 
prescribed opiate-containing formulations for 
cough and dyspnea.
Methods
We retrieved case reports and case series on 
OIRD from the PubMed database written in 
English, Dutch or French during the period 
1980–2013 [5]. Included were cases of patients 
12 years or older who developed OIRD in 
response to opioids during treatment of pain in 
the perioperative setting or emergency depart-
ment, labor pain, cough/dyspnea or procedural 
sedation. Cases related to human errors involv-
ing errors in prescribing or in the programming 
of infusion devices were excluded.
OIRD was defined as a clinical assessment of 
impaired spontaneous ventilation requiring one 
of the following interventions: Mask ventilation; 
effective reversal of OIRD with naloxone and/
or doxapram; endo-tracheal intubation; posi-
tive pressure ventilation followed by unplanned 
admission to an intensive care or monitored 
setting.
Causality between opioid treatment and 
OIRD was established by authors AD and MN, 
and differences in opinion were resolved by con-
sensus. A priori, the cases were divided into those 
published between 1980 and 1999, and those 
between 2000 and 2013, since this chronological 
partition was meaningful in our study of OIRD 
in chronic pain, as well as divided into three 
age groups, namely 12–30, 31–60 and 61 years 
of age or older. The following variables were 
retrieved from each case:gender, age, comor-




The PubMed search resulted in 4798 publica-
tions of which 4693 did not meet inclusion cri-
teria or cited adverse events not deemed causally 
related to opioids by the authors. In total, 105 
case reports were included in our analysis: 70 
reports involving 97 patients during 1980–1999 
[6–75], and 35 involving 37 patients during 
2000–2013 [76–110]. The number of reports 
per year decreased from 4.9 cases per year in 
1980–1999 to 2.9 cases per year in 2000–2013.
●● Patient characteristics
Patient age was not significantly different before 
or after 2000 (Table 1). Men and women were 
equally represented prior to 2000 but women 
outnumbered men 2:1 after 2000. The majority 
of patients had no underlying medical or neuro-
logical disease that predisposed them to OIRD. 
Only 31% of patients prior to 2000 and 43% 
of patients since the year 2000 had comorbid-
ity possibly related to the OIRD. These predis-
positions included sleep-disordered breathing 
(SDB), renal impairment, obesity (BMI >30) 
and pulmonary disease prior to 2000, whereas 
since 2000 comorbidities predisposing to OIRD 
included renal impairment, pulmonary disease, 
neurological disorders and polymorphisms of 
the CYP450 enzyme system (Table 1). The latter 
occurred especially in cases in which metabolites 
produce active compounds (such as in the case 
of tramadol and codeine).
●● Case-related specifics
Morphine was the preeminent opioid used 
in both pre- and post-2000 periods (>30%) 
whereas sufentanil and fentanyl were the next 
most common in the pre- and post-2000 
time periods (Table 2). Alfentanil was only 
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incriminated in OIRD prior to the year 2000. 
Conversely, remifentanil was incriminated in six 
cases, three of which involved Patient-controlled 
analgesia (PCA) for labor pain, all since the year 
2000. Tramadol was reported as cause of OIRD 
in seven cases (six after 2000). The setting in 
which OIRD was most frequently reported was 
perioperative (with 86 and 69% of cases in pre- 
and post-2000 periods, respectively), followed 
by the obstetrical ward. In both periods, neu-
raxial was the most common route of adminis-
tration followed by the intravenous route, both 
nurse administered and PCA.
●● Outcomes
Serious adverse events resulting in hypoxic brain 
damage or death were reported in six (9%) 
patients and two (6%) patients in pre- and 
post-2000 cases, respectively.
Discussion
●● Opioid-induced respiratory depression
In this study, we included reports on 134 
patients that developed OIRD in an acute set-
ting. Opioids have a direct depressant effect 
on neurons that express the MOP (μ-opioid 
peptide) receptor in the respiratory centers of 
the brainstem [111]. Respiratory depression is 
life threatening when depression of respiratory 
neurons exceeds the respiratory stimulatory 
effects of retained CO
2
 or other stimulants, 
such as pain, heightened arousal and visual 
cues. At low opioid dosagesor slow infusion 







) will increase (hyper-





breathing via activation of central and periph-
eral chemoreceptors. When an opioid dose 
becomes a threat to the patient’s safety, breath-
ing activity will decrease further and become 





[112]. While physicians may have some sense of 
‘standard’ dosing regimens, opioid sensitivity is 
highly variable among patients (dose may vary 
by a factor of 40), and care is always required 
when dosing a patient in any acute setting. In 
one of the retrieved case reports, Lötsch et al. 
describe a young female that received morphine 
for postoperative pain relief. Due to the slow 
onset times of morphine (related to the lag time 
needed to cross the blood–brain barrier), the 
patient’s pain was not alleviated immediately 
and further infusions of morphine were given 
eventually leading to a fatal cardiac arrest 
[93]. This was a classic example of the greater 
potency but slower time to onset of opioid 
analgesia in women compared with men as 
described by Sarton et al. [113], a pharmacoki-
netic/pharmacodynamic nuance, unbeknown 
to most physicians. In most cases reports, 
OIRD developed without any indication of an 
obvious overdose, suggesting that OIRD may 
Table 1. Characteristics of all 134 patients described in 105 case reports on critical 
opioid-induced respiratory depression in the acute care setting.
Patient characteristics  Period (year) 
  1980–1999 2000–2013
Number of cases 97 37
Gender: 
– Men, n (%)  











– Median (range), years 
– Cohort 12–30 years, n (%) 
– Cohort 31-60 years, n (%) 












– Sleep-disordered breathing, n (%)
– Renal impairment, n (%)
– Obesity, n (%)
– Pulmonary disease, n (%)
– Neurological disorders, n (%)†















†Includes poliomyelitis, myopathy, encephalopathy, M. Parkinson, Angelman syndrome.
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have been precipitated by other factors, such 
as underlying disease, an inherent (genetic) 
or acquired increased sensitivity to opioids 
(an acquired increase in opioid sensitivity has 
been observed after repetitive hypoxic events in 
children) [114], pharmacokinetic and pharma-
codynamics drug interactions (e.g., the com-
bination of opioids and sedatives may enhance 
the probability of respiratory depression) and 
genetic polymorphisms of genes involved in 
drug metabolism [2,3]. Our analysis indicates 
that opioid sensitivity and OIRD is difficult 
to predict in individual patients. We therefore 
advise careful titration of the opioid to effect, 
with meticulous and preferably continuous 
monitoring of respiratory variables and level 
of consciousness. Furthermore, independent of 
the level of monitoring, it is equally important 
to take into account the known pharmacoki-
netics and dynamics of the opioid as well as all 
patient factors that may enhance the opioid’s 
effects on breathing.
●● Comparison with case reports on OIRD in 
pediatrics & chronic pain
In two previous reports, we presented an anal-
ysis of case reports in pediatric and chronic 
pain patients published since 1980 [2,3]. In our 
review of pediatric case reports, we retrieved 
27 cases in patients 12 years of age or younger 
[2]. In eight cases, OIRD was due to aninad-
vertent overdose, seven of which were fatal. In 
the remaining 19 patients, the most notable 
patterns were:
 ● Morphine administration in patients with 
renal failure causing the accumulation of 
active metabolites;
 ● Morphine intoxication following codeine 
administration in eight patients with 
CYP2D6 gene polymorphisms associated 
with the ultrarapid metabolizer phenotype;
 ● OIRD in patients following adenotonsillec-
tomy for recurrent tonsillitis and/or 
obstructive sleep apnea.
In 42 cases of OIRD in chronic pain patients 
[3], cases published before the year 2000 pre-
dominantly involved morphine in oncology 
patients whereas cases published since 2000 pre-
dominantly involved methadone, transdermal 
fentanyl and oxycodone in patients with chronic 
noncancer pain, most importantly musculoskel-
etal pain. Patient-related factors included renal 
failure and drug interactions on the CYP450 
system.
Table 2. Case-related specifics.
Case characteristics  Period (year) 
  1980–1999 2000–2013
Number of cases 97 37
Drugs involved:
– Morphine, n (%)
– Sufentanil, n (%)
– Fentanyl, n (%)
– Alfentanil, n (%)
– Remifentanil, n (%)
– Codeine, n (%)


















– Perioperative (nonobstetric), n (%)
– Obstetrics, n (%)
– Acute pain, n (%)
– Sedation, n (%)














– Neuraxial, n (%)
– Intravenous, n (%)†
– Intravenous PCA, n (%)











†Bolus or continuous infusion. 
‡Including oral, intramuscular and intra-articular. 
PCA: Patient-controlled analgesia.
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●● Case-related factors
In our current analysis, the following 
case-related factors were apparent:
 ● Morphine was the drug reported most fre-
quently followed by the phenylpiperidines fen-
tanyl and sufentanil, reflecting their frequency 
of use in the perioperative setting. The replace-
ment of alfentanil by remifentanil apparent in 
pre-2000 to post-2000 cases reflects the change 
in popularity and availability of these agents in 
local practice;
 ● Perioperative (postanesthesia care unit and 
ward) and obstetrics accounted for greater than 
85% of the locations of OIRD. The appearance 
of remifentanil-induced OIRD after 2000 in 
obstetric wards reflects a clinical trend in which 
remifentanil PCA replaces local anesthetic-
based epidural analgesia for the treatment of 
labor pain [107,108,110]. Focus on the respiratory 
effects of remifentanil PCA for labor pain is 
required as it is our belief that this form of anal-
gesia will increase significantly in the upcoming 
years;
 ● Neuraxial opioid administration and single 
intravenous administrations accounted for 
more than 70% of the cases.
●● Patient-related factors
In our current analysis, the following 
patient-related factors were apparent:
 ● A greater number of women experienced 
OIRD in cases since 2000. As suggested by a 
recent meta-analysis, women have a greater 
opioid sensitivity compared with men [115]. 
This regards to both analgesia and respiratory 
depression [116]. The meta-analysis showed 
that greater opioid sensitivity in females 
became apparent during prolonged opioid 
treatment periods (>24 h);
 ● The age range of OIRD was 14–85 years and 
not different in pre- and post-2000 periods. 
Our analysis revealed that advanced age was 
not a risk factor for OIRD (see below);
 ● Comorbidities played a causal role in the devel-
opment of OIRD in 31% (pre-2000) and 41% 
(post-2000) of cases. Most prevalent were SDB 
(17 cases) and renal impairment (nine cases). 
Renal impairment will cause the accumulation 
of toxic metabolites (e.g., the accumulation of 
morphine-6-glucuronide following morphine 
treatment) and requires providers to prescribe 
opioids and their active metabolites that are 
cleared through nonrenal pathways. In chil-
dren, SDB has been associated with an increased 
analgesic sensitivity to opioids [114]. Rodents 
exposed to recurrent hypoxic episodes show a 
greater respiratory sensitivity to opioids [117]. 
These are important observations and suggest 
a link between recurrent hypoxic events and 
OIRD, possibly also in the adult population;
 ● Seven cases of tramadol-induced respiratory 
depression are reported [65,89,97,103–105], most of 
which are related to gene duplication of the 
CYP2D6 system (i.e., rapid and ultra-rapid 
metabolizers) causing an excess of the active 
metabolite O-desmethyl tramadol inducing 
respiratory depression, even when just a low 
dose was administered. O-desmethyl tramadol 
has a much greater affinity for the μ-opioid 
receptor than the parent drug.
In an approach similar to ours, Lee and 
Domino recently published a list of factors asso-
ciated with OIRD from the ASA Closed Claims 
Project Database (CCDB) related to malprac-
tice lawsuits during treatment of acute pain 
from 1990 to 2009 [118]. Although the inclusion 
criteria for our data sets differ (published case 
reports vs cases related to claims; global reports 
vs US-based cases) there is agreement among risk 
factors associated with OIRD. In 86 cases, res-
piratory depression associated factors included 
neuraxial pain therapy, evidence of sleep apnea 
and co-medication (i.e., multimodal pain ther-
apy and addition of nonopioid sedatives). In 
contrast to our findings, PCA played an appre-
ciable role as cause of OIRD especially when 
combined with other (non-neuraxial) modes of 
pain therapy. In a third of cases, involvement of 
more than one physician in prescribing opioids 
was associated with respiratory depression. As 
often described, poor communication between 
prescribing physicians and nursesis mentioned 
as contributing to unrecognized and serious res-
piratory depression. Finally, in common with 
our findings, advanced age was not a factor asso-
ciated with respiratory depression. This may be 
related to the higher acceptance of a fatal out-
come from pain therapy in elderly (and possibly 
sicker) patients compared with younger patients.
Prevalance of OIRD
Our analysis of case reports gives us a reli-
able assessment of both case- and patient-related 
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factors of OIRD. However, our analysis does 
not provide an insight in the number of patients 
(i.e., prevalence) experiencing fatal or nonfatal 
OIRD. The number of patients described (n = 
135) is just a small fraction of the total number 
of patients that we know to experience OIRD. 
Also US data from malpractice claims provide 
little information in this respect. For example, 
Lee and Domino describe only 86 cases (period 
1990–2006) in adult perioperative patients, 
while Subramanyam et al. [119] describe 16 and 
six pediatric patients following tonsillectomy that 
had opioid-related fatal and nonfatal respiratory 
depression, respectively. A recent publication 
states that from 1999 to 2010, the number of 
yearly deaths due to opioid overdose has increased 
from 1.4 to 5.3 per 100,000 (US population) or 
approximately 16,000 individuals in 2010 [120]. 
The increase over time paralleled the sale of opi-
oids and admissions for opioid abuse treatment. 
Evidently, this number includes opioid abuse/
misuse outside the medical setting, opioid treat-
ment for chronic and acute pain and palliative 
case, but indicates the enormity of the problem. 
We estimate that nonfatal occurrences of OIRD 
must be a factor of at least 100 greater.
Conclusion
In aggregate, the CCDB data, this analysis of case 
reports in the acute setting, and our previous anal-
yses in chronic pain patients and pediatrics, sup-
port the theory that OIRD is a significant cause 
of preventable morbidity and mortality. Despite 
the presence of associated factors, our analyses 
indicate that OIRD is difficult to predict in any 
one patient and we therefore recommend that as a 
first step in the prevention of OIRD, to carefully 
titrate the patient to effect. Moreover, all patients 
that receive an opioid in the acute setting must 
be adequately observed and continually electroni-
cally monitored. Other measures that may prevent 
OIRD include adequate education of all involved 
in the deliverance of pain therapy and optimizing 
communication between caregivers (nurses and 
doctors). We are aware that these recommenda-
tions are challenging and costly, but not as costly 
as the inadvertent loss of life from well-intended 
but lethal opioid therapy.
Evidently, our analysis prompts further research 
in the analysis of currently available large data sets 
on OIRD, such as may be available from hospital 
data management systems or insurance compa-
nies. This will result in specific factors that may 
be associated or predictive of OIRD. Additionally, 
we would like to encourage physicians to perform 
prospective studies on OIRD, for example, in the 
acute hospital setting (recovery room/PACU) and 
also in the wards where opioids are often adminis-
tered without proper monitoring. Studies as sug-
gested here will bring us forward in the continu-
ous struggle to make opioid therapy safer.
Future perspective
We are looking forward to the development of 
specific nonopioid drugs that prevent respiratory 
depression during opioid therapy. Several types of 
drugs are being developed including ampakines 
and BK-channel blockers. These agents stimulate 
breathing through activation of respiratory centers 
at central (i.e., within the CNS) or peripheral (i.e., 
at the carotid bodies) sites, independent of any 
action at the opioid receptors, and consequently 
offset the reduced breathing from opioids with-
out affecting analgesia. Possibly combining these 
drugs with common opioids will reduce the prob-
ability of opioid-related morbidity and mortality. 
Still vigilance remains required and development 
of sophisticated monitoring tools in patients tak-
ing potent opioids and patients with comorbidity 
prone to develop respiratory depression is addi-
tionally required. We envision the development 
of telemetric monitors of the cardiorespiratory 
system attached to smart sensors embedded in 
watches, smartphones or garments. Yet again, 
these approaches may not result in the (false) feel-
ing of safety, as opioids remain potentially fatal 
under all conditions.
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